107 related articles for article (PubMed ID: 23978989)
1. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G
Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989
[TBL] [Abstract][Full Text] [Related]
2. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
Koonce NA; Griffin RJ; Dings RPM
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232825
[TBL] [Abstract][Full Text] [Related]
4. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
Gheysen L; Soumoy L; Trelcat A; Verset L; Journe F; Saussez S
Cells; 2021 May; 10(5):. PubMed ID: 34063063
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
6. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
8. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
Leung Z; Ko FCF; Tey SK; Kwong EML; Mao X; Liu BHM; Ma APY; Fung YME; Che CM; Wong DKH; Lai CL; Ng IO; Yam JWP
J Exp Clin Cancer Res; 2019 Oct; 38(1):423. PubMed ID: 31640796
[TBL] [Abstract][Full Text] [Related]
9. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
10. Effects of galectin-1 inhibitor OTX008 on oral squamous cell carcinoma cells in vitro and the role of AP-1 and the MAPK/ERK pathway.
Greer PFC; Rich A; Coates DE
Arch Oral Biol; 2022 Feb; 134():105335. PubMed ID: 34891102
[TBL] [Abstract][Full Text] [Related]
11. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
12. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang XL; Zhang Y; Luo CL; Wu XH
Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
Hu J; Zong Y; Li J; Zhou X; Zhang J; Zhu T; Jiao M; Su H; Bo B
J Ultrasound Med; 2016 Mar; 35(3):589-97. PubMed ID: 26921089
[TBL] [Abstract][Full Text] [Related]
14. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
15. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
17. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
19. Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
DeVorkin L; Hattersley M; Kim P; Ries J; Spowart J; Anglesio MS; Levi SM; Huntsman DG; Amaravadi RK; Winkler JD; Tinker AV; Lum JJ
Mol Cancer Res; 2017 Mar; 15(3):250-258. PubMed ID: 28184014
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
